Leukemia Clinical Trials in Minneapolis

Showing 301-320 of 610 trials

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

NCT03054909

This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.

FIGO Stage III and IV Ovarian CancerFIGO Stage III and IV Fallopian Tube CancerFIGO Stage III Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota7 participantsStarted Sep 2017

Minneapolis, Minnesota, United States

COMPLETEDPHASE2< 1 mile

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

NCT02873338

This was an exploratory Phase 2, open label, randomized, multicenter, parallel group study to determine whether there was evidence that the addition of dociparstat (CX-01) at 2 different does levels to standard induction therapy (cytarabine+idarubicin, "7+3") and consolidation therapy had an additive therapeutic effect for subjects newly diagnosed with acute myeloid leukemia (AML) when compared with subjects receiving standard induction chemotherapy alone.

Acute Myeloid Leukemia

Jazz Pharmaceuticals75 participantsStarted Aug 2016

La Jolla, California, United States • Denver, Colorado, United States • Washington D.C., District of Columbia, United States +20 more locations

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Leukemia Trials in Other Cities

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Other Conditions in Minneapolis